168 related articles for article (PubMed ID: 26196503)
21. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.
Roué G; López-Guerra M; Milpied P; Pérez-Galán P; Villamor N; Montserrat E; Campo E; Colomer D
Clin Cancer Res; 2008 Nov; 14(21):6907-15. PubMed ID: 18980985
[TBL] [Abstract][Full Text] [Related]
22. Bendamustine treatment in a heavily pretreated Hodgkin lymphoma patient.
Elsoueidi R; Mulat A; Mourad H
J Oncol Pharm Pract; 2014 Aug; 20(4):309-11. PubMed ID: 24847047
[TBL] [Abstract][Full Text] [Related]
23. Stabilities of neutral and basic esters of bendamustine in plasma compared to the parent compound: kinetic investigations by HPLC.
Huber S; Antoni F; Schickaneder C; Schickaneder H; Bernhardt G; Buschauer A
J Pharm Biomed Anal; 2015 Feb; 104():137-43. PubMed ID: 25499654
[TBL] [Abstract][Full Text] [Related]
24. Bendamustine increases interleukin-10 secretion from B cells via p38 MAP kinase activation.
Lu L; Yoshimoto K; Morita A; Kameda H; Takeuchi T
Int Immunopharmacol; 2016 Oct; 39():273-279. PubMed ID: 27500457
[TBL] [Abstract][Full Text] [Related]
25. Bendamustine: inadequate or outdated data.
Prescrire Int; 2012 Mar; 21(125):64. PubMed ID: 22428184
[TBL] [Abstract][Full Text] [Related]
26. Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data.
Palumbo A; Offidani M; Patriarca F; Petrucci MT; Cavo M
Leuk Lymphoma; 2015 Mar; 56(3):559-67. PubMed ID: 24884319
[TBL] [Abstract][Full Text] [Related]
27. Establishment and Characteristics of a Novel Mantle Cell Lymphoma-derived Cell Line and a Bendamustine-resistant Subline.
Takimoto-Shimomura T; Nagoshi H; Maegawa S; Fujibayashi Y; Tsukamoto T; Matsumura-Kimoto Y; Mizuno Y; Chinen Y; Mizutani S; Shimura Y; Horiike S; Taniwaki M; Kobayashi T; Kuroda J
Cancer Genomics Proteomics; 2018; 15(3):213-223. PubMed ID: 29695404
[TBL] [Abstract][Full Text] [Related]
28. Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Elefante A; Czuczman MS
Am J Health Syst Pharm; 2010 May; 67(9):713-23. PubMed ID: 20410545
[TBL] [Abstract][Full Text] [Related]
29. Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
Martin P; Chen Z; Cheson BD; Robinson KS; Williams M; Rajguru SA; Friedberg JW; van der Jagt RH; LaCasce AS; Joyce R; Ganjoo KN; Bartlett NL; Lemieux B; VanderWalde A; Herst J; Szer J; Bar MH; Cabanillas F; Dodds AJ; Montgomery PG; Pressnail B; Ellis T; Smith MR; Leonard JP
Br J Haematol; 2017 Jul; 178(2):250-256. PubMed ID: 28419413
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites.
Darwish M; Bond M; Hellriegel E; Robertson P; Chovan JP
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1143-54. PubMed ID: 25829094
[TBL] [Abstract][Full Text] [Related]
31. Bendamustine's emerging role in the management of lymphoid malignancies.
Rummel MJ; Gregory SA
Semin Hematol; 2011 Apr; 48 Suppl 1():S24-36. PubMed ID: 21530769
[TBL] [Abstract][Full Text] [Related]
32. Potent and Selective Inhibition of Plasma Membrane Monoamine Transporter by HIV Protease Inhibitors.
Duan H; Hu T; Foti RS; Pan Y; Swaan PW; Wang J
Drug Metab Dispos; 2015 Nov; 43(11):1773-80. PubMed ID: 26285765
[TBL] [Abstract][Full Text] [Related]
33. Interaction of human organic anion transporter 2 (OAT2) and sodium taurocholate cotransporting polypeptide (NTCP) with antineoplastic drugs.
Marada VV; Flörl S; Kühne A; Müller J; Burckhardt G; Hagos Y
Pharmacol Res; 2015 Jan; 91():78-87. PubMed ID: 25481222
[TBL] [Abstract][Full Text] [Related]
34. Bendamustine associated immune suppression and infections during therapy of hematological malignancies.
Gafter-Gvili A; Polliack A
Leuk Lymphoma; 2016; 57(3):512-9. PubMed ID: 26696321
[TBL] [Abstract][Full Text] [Related]
35. Cross-resistance and synergy with bendamustine in chronic lymphocytic leukemia.
Kost SE; Bouchard ED; LaBossière É; Ye X; Queau ML; Liang WS; Banerji V; Gibson SB; Katyal S; Johnston JB
Leuk Res; 2016 Nov; 50():63-71. PubMed ID: 27683974
[TBL] [Abstract][Full Text] [Related]
36. Nanosized complexation assemblies housed inside reverse micelles churn out monocytic delivery cores for bendamustine hydrochloride.
Singh Y; Chandrashekhar A; Meher JG; Durga Rao Viswanadham KK; Pawar VK; Raval K; Sharma K; Singh PK; Kumar A; Chourasia MK
Eur J Pharm Biopharm; 2017 Apr; 113():198-210. PubMed ID: 28088632
[TBL] [Abstract][Full Text] [Related]
37. Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1).
Nies AT; Herrmann E; Brom M; Keppler D
Naunyn Schmiedebergs Arch Pharmacol; 2008 Feb; 376(6):449-61. PubMed ID: 18157518
[TBL] [Abstract][Full Text] [Related]
38. High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients.
Prediletto I; Farag SA; Bacher U; Jeker B; Mansouri Taleghani B; Brégy R; Zander T; Betticher D; Egger T; Novak U; Pabst T
Bone Marrow Transplant; 2019 Dec; 54(12):1923-1925. PubMed ID: 30890768
[No Abstract] [Full Text] [Related]
39. Population pharmacokinetics and pharmacokinetics/pharmacodynamics of bendamustine in pediatric patients with relapsed/refractory acute leukemia.
Darwish M; Megason G; Bond M; Hellriegel E; Robertson P; Grasela T; Phillips L
Curr Med Res Opin; 2014 Nov; 30(11):2305-15. PubMed ID: 25105914
[TBL] [Abstract][Full Text] [Related]
40. Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines.
Konstantinov SM; Kostovski A; Topashka-Ancheva M; Genova M; Berger MR
J Cancer Res Clin Oncol; 2002 May; 128(5):271-8. PubMed ID: 12029443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
